Presentation

Company Profile
Intervacc is a biotech company primarily focusing on the development of sub-unit vaccines against economically important bacterial infections within animal health. The pipeline is based on new technology using recombinant proteins rather than attenuated live strains found in conventional vaccines. This results in much lower incidence of side effects. The vaccine candidates are based on research at Karolinska Institutet and Swedish University of Agricultural Research. Strangvac is the lead candidate, a vaccine against equine strangles, a highly contagious infectious disease affecting horses. Intervacc has its own sales organisation in the Nordics and the Baltics through its subsidiary Nordvacc Läkemedel AB.

Recent highlights
In April 2021, Intervacc announced that it entered into an agreement with distributor Dechra Pharmaceuticals PLC to commercialise Strangvac® in Europe. The agreement will run for 5 years, and it excludes the Nordic and Baltic countries where Intervacc will directly market and sell Strangvac® themselves. IN May, the company announced that it signed a multi-year agreement with Karolinska Institute for the development of animal health vaccines. During the months of July and August, the company has received marketing authorisation for its Strangvac vaccine by the European Commission, the VMD in the UK and the Norwefian Medicines Agency.

Outlook
With their lead assed receiving marketing approval by various authorities, the focus of the company now lies on the commercialisation efforts. Furthermore, the advancement of their preclinical pipeline could progress, with 2 programmes currently active.